Baird raised the firm’s price target on Alcon to $95 from $90 and keeps an Outperform rating on the shares. The firm said with cataract and contact lens demand trends holding in well, pricing tailwinds persisting, and Fx/inflationary headwinds likely abating later this year/into 2024, they continue to see a fairly clear path to MSD+ organic revenue growth/healthy margin expansion for Alcon over coming years.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ALC: